Please login (Members) to view content or
(Nonmembers) this article.
No votes yet

Amifostine as a Radioprotectant

Tracy K. Gosselin
Beatrice Mautner
Kathy Wilkinson
CJON 2002, 6(3), 175-176 DOI: 10.1188/02.CJON.175-176

Amifostine is used as a radioprotectant in patients undergoing postoperative radiation therapy for head and neck cancer, where the radiation port includes a substantial portion of the parotid glands to reduce or prevent acute or late xerostomia. Amifostine also is used in conjunction with chemotherapy to decrease the incidence or severity of neurotoxicity, nephrotoxicity, and hematologic toxicity. Amifostine is used to minimize treatment-related sequelae without reducing the antitumor efficacy of chemotherapy or radiation therapy.

Members Only

Access to this article is restricted. Please login to view the full article.

Not a current ONS Member or journal subscriber?
Join/Renew Membership or